prof. dr. G.N. (Gert) Moll

Honorary professor Protein Modification and Functionality

Faculteit Science and Engineering

Telefoon:

050 36 32111

E-mail:

g.n.moll rug.nl

ORCID Research Portal

Publicaties

Advances in the therapeutic potentials of ligands of the apelin receptor APJ

Wagenaar, G. T. M. & Moll, G. N., 15-mrt.-2025, In: European Journal of Pharmacology. 14 blz., 177302.

Onderzoeksoutput › peer review

Clinical significance of intervention in the renin-angiotensin-aldosterone-apelinergic system

Wagenaar, G. T. M. & Moll, G. N., 15-sep.-2025, In: European Journal of Pharmacology. 1003, 11 blz., 177866.

Onderzoeksoutput › peer review

Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer

Moll, G. N., 5-sep.-2024, In: European Journal of Pharmacology. 978, 8 blz., 176772.

Onderzoeksoutput › peer review

AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung remodelling

Villela, D. C., Namsolleck, P., Reichetzeder, C. & Moll, G. N., 2023, In: Peptides. 170, 9 blz., 171106.

Onderzoeksoutput › › peer review

Evolving views on the first two ligands of the angiotensin II type 2 receptor. From putative antagonists to potential agonists?

Wagenaar, G. T. M. & Moll, G. N., 15-dec.-2023, In: European Journal of Pharmacology. 961, 8 blz., 176189.

Onderzoeksoutput › peer review

Galanin 2 Receptor: A Novel Target for a Subset of Pancreatic Ductal Adenocarcinoma

Namsolleck, P., Kofler, B. & Moll, G. N., 15-jun.-2023, In: International Journal of Molecular Sciences. 24, 12, 9 blz., 10193.

Onderzoeksoutput › › peer review

LP2, a cyclic angiotensin-(1−7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice

Namsolleck, P., de Vries, L. & Moll, G. N., feb.-2023, In: Peptides. 160, 170920.

Onderzoeksoutput › › peer review

Alle (68) publicaties

Pers/media

Uit RUG voortgekomen Lanthio Pharma Chemische Start-up van het Jaar

Moll, G.

24/11/2014

Pers / media: Activiteiten met een maatschappelijk belang ›

Alle (1) pers/media

Bekijk volledig onderzoeksprofiel

prof. dr. G.N. (Gert) Moll

Publicaties

Advances in the therapeutic potentials of ligands of the apelin receptor APJ

Clinical significance of intervention in the renin-angiotensin-aldosterone-apelinergic system

Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer

AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung remodelling

Evolving views on the first two ligands of the angiotensin II type 2 receptor. From putative antagonists to potential agonists?

Galanin 2 Receptor: A Novel Target for a Subset of Pancreatic Ductal Adenocarcinoma

LP2, a cyclic angiotensin-(1−7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice

LP2, a stable lanthipeptide derived from cAng-(1-7), exerts myeloprotective action in mice

Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake

LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study

Pers/media

Uit RUG voortgekomen Lanthio Pharma Chemische Start-up van het Jaar